This report was first published by Endpoints News. To see the original version, click here
Wall Street’s expectations for Bristol Myers Squibb’s upcoming slate of data readouts are reaching a fever pitch.
Analysts lobbed questions regarding at least half a dozen trial results expected by the end of 2026, in a year that’s shaping up to be a pivotal one for Bristol Myers. The studies will help BMS chart its future as the company manages two looming patent cliffs for the blood thinner Eliquis and immunotherapy Opdivo.
您已阅读16%（518字），剩余84%（2797字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。